Literature DB >> 7593607

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

R Simantov1, J M LaSala, S K Lo, A E Gharavi, L R Sammaritano, J E Salmon, R L Silverstein.   

Abstract

Circulating antiphospholipid antibodies (aPL) are associated with a syndrome of thrombosis, recurrent fetal loss, and thrombocytopenia. We have demonstrated the activation of cultured human umbilical vein endothelial cells (HUVEC) by IgG from patients with anticardiolipin antibodies (aCL). Incubation of HUVEC for 4 h with purified IgG (100 micrograms/ml) from patients with high-titer aCL induced a 2.3-fold increase in monocyte adhesion over that seen in HUVEC incubated with IgG's from normal subjects. The effect of aCL was not attributable to LPS contamination, Fc receptors, or immune complexes. Monocyte adhesion was not induced when the aCL were added in serum-free media but was restored by the addition of purified beta 2GP1, previously described as a necessary cofactor for aCL reactivity. Purified rabbit polyclonal IgG raised against beta 2GP1 also induced monocyte adhesion when incubated with HUVEC. Preadsorption of patient serum with cardiolipin reduced monocyte adhesion by 60%. Immunofluorescent microscopy demonstrated that endothelial cells incubated with patient IgG expressed cell adhesion molecules, including E-selectin, vascular cell adhesion molecule-1, and intracellular adhesion molecule-1. These data support the hypothesis that aPL activate vascular endothelial cells, thereby leading to a pro-thrombotic state.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593607      PMCID: PMC185871          DOI: 10.1172/JCI118276

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Biologic activity of aggregated gamma-globulin. II. A study of various methods for aggregation and species differences.

Authors:  K ISHIZAKA; T ISHIZAKA
Journal:  J Immunol       Date:  1960-08       Impact factor: 5.422

2.  IgG anti-cardiolipin antibodies in murine lupus.

Authors:  A E Gharavi; R C Mellors; K B Elkon
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

Review 3.  Anti-phospholipid antibodies.

Authors:  E N Harris; A E Gharavi; G R Hughes
Journal:  Clin Rheum Dis       Date:  1985-12

4.  Investigations on beta 2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions.

Authors:  E Polz; H Wurm; G M Kostner
Journal:  Int J Biochem       Date:  1980

5.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

6.  Complete amino acid sequence of human plasma beta 2-glycoprotein I.

Authors:  J Lozier; N Takahashi; F W Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

7.  Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

Authors:  A E Gharavi; E N Harris; R A Asherson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

8.  Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes.

Authors:  H W Ziegler-Heitbrock; E Thiel; A Fütterer; V Herzog; A Wirtz; G Riethmüller
Journal:  Int J Cancer       Date:  1988-03-15       Impact factor: 7.396

9.  Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus.

Authors:  D B Cines; A P Lyss; M Reeber; M Bina; R J DeHoratius
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

10.  Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines.

Authors:  M P Bevilacqua; J S Pober; M E Wheeler; R S Cotran; M A Gimbrone
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

View more
  71 in total

Review 1.  Clinical trials for the antiphospholipid syndrome.

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 2.  Antiphospholipid antibodies and the endothelium.

Authors:  B J Hunt; M A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 3.  Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis.

Authors:  J E Salmon; G Girardi; V M Holers
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

4.  Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides.

Authors:  M Blank; Y Shoenfeld; S Cabilly; Y Heldman; M Fridkin; E Katchalski-Katzir
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  Complement system on the attack in autoimmunity.

Authors:  John P Atkinson
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 6.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

7.  Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome.

Authors:  C Hamid; K Norgate; D P D'Cruz; M A Khamashta; M Arno; J D Pearson; G Frampton; J J Murphy
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

Review 8.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 9.  Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy.

Authors:  Waqar Haque; Huseyin Kadikoy; Omar Pacha; Joseph Maliakkal; Vu Hoang; Abdul Abdellatif
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

10.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.